• Gen-Orph

    Providing patients and physicians
    with effective and high quality medicines

  • Our mission

    Easy access to effective, useful and effective medicines.

    Gen.Orph obtained successfully the pharmaceutical status in March 2017.

    Operational start was in January 2018.

    broken image

    Gen.Orph focuses all it’s efforts on the healthcare of national and international patients : 

    - Medicines for Orphan disease, that are effective and affordable

    - Medicines with attractive medical and economic potential

    - Innovative medicines for common diseases

  • Our products

    Our orphan drugs for the treatment of rare diseases

    broken image

    GEN-ORPH 1

    Miglustat GEN-ORPH

    Treatment of Iysosomal storage disorders
     

    Indications:
    Gaucher disease Typ 1
    Niemann-Pick Typ C disease
     

    Launches:
    2018: France, Sweden, Norway and Finland
    2019: Italy, Bulgaria and Germany
    2020: Portugal, Serbia, Czech Republic, Ungary, Poland, Slowakia, Slowenia, England, Greece, Austria, Saudi Arabia and Latin America

    broken image

    GEN-ORPH 2

    Cinacalcet GEN-ORPH

    Orphan Drug for the treatment of rare diseases


    Indications:
    Secondary hyperparathyroidism in patients with dialysis kidney failure associated with Phosphate binders and vitamin D, since September 2017 also approved for children over the age of three Hypercalcemia in parathyroid carcinoma
     

    Cinacalcet Gen.Orph is about to register in some European
    countries

     

    Launches:
    Q2 2020, after patent expiry of the original preparation

    broken image

    GEN-ORPH 3

    Orphan drugs for the treatment of rare diseases

     

    Gen.Orph 3 is under development and gets into a decentralized process
    registered at European level.

     

    Launch planned in Q4 2020

  • To consult the summary of the characteristics produced, the notice, the opinion of the Transparency Commission, refer to the following link:

    http://base-donnees-publique.medicaments.gouv.fr/

     

     

    Other Commercialized Products from Gen.Orph

    broken image

    Agyrax, Postafen, Navidoxine

    Meclozine Chlorhydrat

    Available in France, Sweden, Norway, Finland, Danmark, Iceland, Malta, Senegal and Ivory coast.

     

    Indications:
    Prevention and treatment of motion sickness
    Treatment of dizziness
    Treatment for nausea and vomiting pregnant women in Sweden.

    broken image

    Sitavig

    Aciclovir Lauridad

    Launched in the US, Italy and France

     

    Indications:
    Treatment of recurring herpes simplex in patients with frequent episodes.

  • Pharmacovigilance

    All medicines can have side effects. If you suspect any side effect, whether or not it is listed in the package leaflet, talk to your doctor or pharmacist. This also applies to any effect that is not mentioned in the package leaflet. You can also report suspected adverse reactions directly via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM): www.signalement-sante.gouv.fr Our laboratory is at your service to provide you with any information concerning our specialties. To report an adverse reaction or have medical information, you can reach us by email: PR@gen-orph.com or by phone: +33 (0) 1.47.71.04.50  

    General Data Protection Regulation

    GEN-ORPH respects your privacy and protects your personal information. Your personal data will be processed in accordance with the notices on data in the European Economic Area concerning medical information, product information and the safety of medicinal products. If you have questions about the use of your personal information by GEN-ORPH or would like to receive them by e-mail or post, please contact us by e-mail or telephone.

     

    Interests between the pharmaceutical companies and health professionals / and other stakeholders in the healthcare system will be published on the Internet in accordance with the law of 29 December 2011 on health security and its decree of 21 May 2011, which will improve the transparency of the entire health system.

  • Research and Development

    Further products are currently in the development phase

    broken image

  • The Team

    Etienne Jacob

    CEO
    Founder

    Medical doctor

    Pitié-Salpetriere, Paris

    Harvard Business School – AMP

    Patrice Layrac

    Director
    Founder

    Master in Economics at the
    Universität de Paris Dauphine et

    IEP INSEAD

    Eric Lille

    CFO

    Dr. A.M. Charrier

    Regulatory Affairs

    Jocelyn Lejay

    Responsible Person back up

    Franck Grodenic

    Responsible person
    industriel

    Anna Biedermann

    Commercial Management
    and Supply Chain

    Etienne Horreard

    Responsible Person

  • Contact us

    1 rue royale, 92210 Saint-Cloud
    +33(0)147710450
    +33(0)147710450
    contact@gen-orph.com
    Utilisation des cookies
    Nous utilisons des cookies pour assurer une expérience de navigation fluide. En continuant, nous supposons que vous acceptez l'utilisation des cookies.
    En savoir plus